Mirtazepine: heir apparent to amitriptyline?
"What's new in therapeutics?" will examine and evaluate drugs that may have a place in hospice, palliative, and long-term care. Mirtazepine will be examined and evaluated. Mirtazepine is a potential alternative anti-depressant with multiple additional benefits. It is an atypical anti-depressant, which has both noradrenergic and specific serotonergic receptor antagonism (NaSSa), and a unique pharmacological profile. Mirtazepine appears to be a "designer drug" for palliative medicine with a number of benefits, but cost may be a drawback.
Davis
M P
MP
Harry R. Horvitz Center for Palliative Medicine, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA.
Dickerson
E D
ED
Pappagallo
M
M
Benedetti
C
C
Grauer
P A
PA
Lycan
J
J
D000639:Amitriptyline / Q000627:therapeutic use*; D000929:Antidepressive Agents, Tricyclic / Q000145:classification / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D016527:Drug Costs; D018954:Drugs, Essential / Q000627:therapeutic use; D006634:Histamine H1 Antagonists / Q000145:classification / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008803:Mianserin / Q000031:analogs & derivatives / Q000145:classification / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D000078785:Mirtazapine; D018579:Patient Selection; D013727:Terminal Care / Q000379:methods*
D000929:Antidepressive Agents, Tricyclic; D018954:Drugs, Essential; D006634:Histamine H1 Antagonists; D000639:Amitriptyline; D008803:Mianserin; D000078785:Mirtazapine